DOCSLIB.ORG

Barbexaclone Use in Pregnancy Oxcarbazepine During the Breast Feeding Period

Total Page：16

File Type：pdf, Size：1020Kb

Download full-text PDF Read full-text
Barbexaclone Use in Pregnancy Oxcarbazepine During the Breast Feeding Period Age of menarche in Jordanian girls Acknowledgment. We are grateful to Dr. M. A 36-year-old caucasian woman, multigravida Ammari in collecting the data. case had begun to use barbexaclone 300 mg/day and oxcarbazepine 600 mg/day, for 2 years before the Received 10th June 2003. Accepted for publication in final form 13th September 2003. pregnancy, due to epilepsy and continued to use both drugs until the end of week 10 of her From the Department of Medicine, Jordan University of Science and pregnancy. When she became aware of pregnancy, Technology, Irbid, Jordan. Address correspondence and reprint requests to Dr. Fawaz Ammari, Department of Medicine, Jordan she decided to quit taking barbexaclone with our University of Science and Technology, PO Box 3030, Irbid 22110, recommendation, as there was no data regarding this Jordan. Tel/Fax. +962 (2) 7095010. E-mail: dr_fammari@hotIntroduction drug regarding human or animal pregnancy. Oxcarbazepine 1200 mg/day was continued until the References end of pregnancy. She did not use folic acid before or during the pregnancy. No clinical worsening in 1. Saar E, Shalev C, Dalal I, Sod-Moriah UA. Age at epilepsy was observed after withdrawal of menarche: The influence of environmental condition. Int J barbexaclone. She had a history of one therapeutic Biometeorol 1988; 32: 33-35. 2. Manniche E. Age at menarche: Nicolai Edvard Ravn’s data abortion due to carbamazepine use and one on 3385 women in mid-19th century Denmark. Ann Hum spontaneous abortion. All obstetrical and Biol 1983; 10: 79-82. ultrasonographical findings of the present pregnancy 3. Attallah NL, Matta WM, El-Mankonshi M. Age at menarche of schoolgirls in Khartoum. Ann Hum Biol were found normal. Due to maternal serum 1983; 10: 185-188. alpha-fetoprotein was low (0.36 MoM; Multiples of 4. Kak G, Auxiliadora de Sonata Cruz C, Median) in the sixteenth week, the case underwent Velazquez-Melendez G. Secular trend in age at menarche amniocentesis. No chromosomal abnormality was for women born between 1920-1979 in Rio de Janeiro, Brazil. Ann Hum Biol 2000; 27: 423-428. found by amniocentesis in the eighteenth week. The 5. Floris G, Murgia E, Sancia GM, Sanna E. Age at menarche patient elected to have sectio delivery at 37 weeks in Sardinia (Italy). Ann Hum Biol 1987; 14: 285-286. of gestation and had a female infant (3.2 kg, 49 cm) ----------------------------------------------------------------------------- with APGAR scores of 9 and 10, by an uncomplicated delivery. The case continued to use Barbexaclone use in pregnancy oxcarbazepine during the breast feeding period. The baby was followed for 2 years, and no major congenital abnormalities or minor malformations Fusun Yaris, MD, PhD, Mine Kadioglu, MD, were observed based on physical examinations. Her Murat Kesim, MD, Cunay Ulku, MD, Ersin Yaris, MD, PhD, Nuri I. Kalyoncu, MD physical, motor and mental development at 24 months of age was completely normal. Pregnancy in epileptic women is known to be associated with a rug exposure in pregnancy is a complex problem higher risk of congenital malformations than D for obstetricians. Epilepsy is the most common non-epileptic pregnant women. The offspring of serious chronic neurological condition with a women with epilepsy are at increased risk for prevalence of 4-10/1000, and most of epileptic congenital malformation, but the impact of the patients, including women of childbearing years various contributing factors remains unresolved.1,2 (25% of total epileptic populations), require Bokhari et al4 reported strong association between treatment with anti-epileptic drugs. Due to potential the presence of coned epiphyses in feet and hands, teratogenic side effects of the antiepileptic drugs, but could not be considered a distinctive feature of risks and benefits of the drugs must be assessed for teratogenicity of phenytoin and phenobarbital. The both the mother and fetus.1,2 Barbiturates and frequency of epileptic seizure may be altered by pregnancy and seizures may cause complications in phenytoin are particularly associated with pregnancy. Hypoxic conditions caused by epileptic congenital heart malformations, facial clefts and 1,3 seizures may affect the fetus in a serious or negative some other malformations. Barbexaclone is a way.1,2 All these issues must be considered in the levopropylhexedryn salt of barbiturate, and no treatment of epileptic pregnant women. The available data are present in the literature about incidence of malformations due to the use of pregnant women, who used barbexaclone alone or oxcarbazepine was found 8% and 5% in the drug in combination with any other drug. We are group and control groups in mice, and this reporting on a patient who used barbexaclone for 2 difference was not statistically significant.5 years before pregnancy and during the first 10 Carbamazepine, phenytoin and valproic acid have weeks of the pregnancy. A physician, was unaware been shown to be associated with teratogenicity, but of the pregnancy, and prescribed the drug. a lower risk was observed with oxcarbazepine www.smj.org.sa Saudi Med J 2004; Vol. 25 (2) 245 Barbexaclone use in pregnancy compared to the other agents.1,5 As the first choice No evidence of persistent drug, oxcarbazepine can be used as monotherapy at helicobacter pylori infection in the lowest effective dose in the treatment of peripheral blood of patients with epileptic syndrome.1 Careful planning and management of any pregnancy in women with coronary heart disease epilepsy is essential to increase the likelihood of a healthy outcome for both mother and infant.1,2 In our case, pregnancy had not been planned; antiepileptic Abdulaziz S. Al-Khattaf, MSc, PhD. drugs were used during the first 10 weeks of the R pregnancy. After consultation among physicians ecently, it was proposed that coronary heart within our departments, we recommended that she disease (CHD) may be associated with chronic stop taking barbexaclone due to lack of data in the helicobacter pylori infection.1 The data, however, literature regarding its effects on pregnant women. are conflicting since there are reports denying the In the light of the previous studies, we link between the 2 conditions.2 Similarly, there have recommended oxcarbazepine as a monotherapy that been several claims of strong and significant could be taken throughout the remainder of her correlation between chronic H. pylori infection and pregnancy. Oxcarbazepine seems to be safer than various vascular risk factors such as fibrinogen other available agents. Diet before conception and concentration and white cell count.3 The presence of during organogenesis should contain adequate high concentration of immunoglobulin G antibodies amounts of folic acid. This is valid also for pregnant to H. pylori has been associated with chronic gastric women using antiepileptic drugs, but our patient did infection.4 Association of chronic H. pylori infection not elect to use folic acid upon our recommendation. with CHD was established on the bases of the In the literature, this is the first case of an evidence that antibodies against H. pylori were observation of barbexaclone exposure in a pregnant detected in sera of 76.6% of patients with CHD.3 woman. We did not find any congenital anomaly in Since antibodies against H. pylori are also present in the baby. This single case is not enough to define the sera of other wise normal healthy individuals the drug as "safe in pregnancy," but we wish to and the significance of these antibodies in sera of share this information with the other physicians. patients with CHD and their association with CHD remains doubtful.5 In order to investigate the Received 28th July 2003. Accepted for publication in final form 20th October 2003. association between persistent H. pylori infection and CHD this study was performed to detect the From the Department of Family Medicine (Yaris), Department of presence of H. pylori DNA in the peripheral blood Pharmacology (Kadioglu, Kesim, Ulku, Yaris, Kalyoncu), School of Medicine, Karadeniz Technical University, Trabzon, Turkey. Address of patients with CHD by polymerase chain reaction correspondence and reprint requests to Dr. Murat Kesim, Department (PCR). of Pharmacology, School of Medicine, Karadeniz Technical University, TR-61187, Tabzon, Turkey. Tel. +90 (462) 3775306. Fax. +90 (462) Sera from 20 male patients, with mean age of 54 3775498. E-mail: [email protected] ± 5, diagnosed as having CHD according to the World Health Organization criteria of non-fatal References myocardial infraction, and 12 healthy blood donors with mean age of 56 ± 5 with no history of any 1. Morrow JI, Craig JJ. Anti-epileptic drugs in pregnancy: current safety and other issues. Expert Opin Pharmacother significant illness in the past were tested. Ten ml of 2003; 4: 445-456. blood was collected by venipuncture in sterile tube, 2. Barrett C, Richens A. Epilepsy and pregnancy: Report of an and was allowed to clot at 40C for 2-4 hours. Serum Epilepsy Research Foundation Workshop. Epilepsy Res was separated from whole blood by centrifugation at 2003; 52: 147-148. 1200 x g for 20 minutes at room temperature, and 3. Lindhout D, Omtzigt JG. Pregnancy and the risk of stored at –200C until used. Table 1 illustrates the teratogenicity. Epilepsia 1992; 33 Suppl 4: S41-48. 4. Bokhari A, Connolly S, Coull BA, Harvey EA, Holmes LB, structural design of primers and capture probe used Bokhari A. Effects on toes from prenatal exposure to in this study. The selection of primers and capture anticonvulsants. Teratology 2002; 66: 122-126. (Erratum probe was based on the sequence ure C, and had in: Teratology 2002; 66: 348-349). been used in a previously published study.6 5. Bennett GD, Amore BM, Finnell RH, Wlodarczyk B, Serum sample was lysed using lysis buffer with Kalhorn TF, Skiles GL et al. Teratogenicity of Proteinase K and was precipitated in ethanol, which carbamazepine-10, 11-epoxide and oxcarbazepine in the SWV mouse.
Load more

Recommended publications
  • (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 De Juan Et Al
    US 200601 10428A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2006/0110428A1 de Juan et al. (43) Pub. Date: May 25, 2006 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA (US); A6F 2/00 (2006.01) Signe E. Varner, Los Angeles, CA (52) U.S. Cl. .............................................................. 424/427 (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Correspondence Address: Featured is a method for instilling one or more bioactive SCOTT PRIBNOW agents into ocular tissue within an eye of a patient for the Kagan Binder, PLLC treatment of an ocular condition, the method comprising Suite 200 concurrently using at least two of the following bioactive 221 Main Street North agent delivery methods (A)-(C): Stillwater, MN 55082 (US) (A) implanting a Sustained release delivery device com (21) Appl. No.: 11/175,850 prising one or more bioactive agents in a posterior region of the eye so that it delivers the one or more (22) Filed: Jul. 5, 2005 bioactive agents into the vitreous humor of the eye; (B) instilling (e.g., injecting or implanting) one or more Related U.S. Application Data bioactive agents Subretinally; and (60) Provisional application No. 60/585,236, filed on Jul. (C) instilling (e.g., injecting or delivering by ocular ion 2, 2004. Provisional application No. 60/669,701, filed tophoresis) one or more bioactive agents into the Vit on Apr. 8, 2005. reous humor of the eye. Patent Application Publication May 25, 2006 Sheet 1 of 22 US 2006/0110428A1 R 2 2 C.6 Fig.
    [Show full text]
  • List of Union Reference Dates A
    Active substance name (INN) EU DLP BfArM / BAH DLP yearly PSUR 6-month-PSUR yearly PSUR bis DLP (List of Union PSUR Submission Reference Dates and Frequency (List of Union Frequency of Reference Dates and submission of Periodic Frequency of submission of Safety Update Reports, Periodic Safety Update 30 Nov. 2012) Reports, 30 Nov.
    [Show full text]
  • Partial Agreement in the Social and Public Health Field
    COUNCIL OF EUROPE COMMITTEE OF MINISTERS (PARTIAL AGREEMENT IN THE SOCIAL AND PUBLIC HEALTH FIELD) RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies, and superseding Resolution AP (82) 2) AND APPENDIX I Alphabetical list of medicines adopted by the Public Health Committee (Partial Agreement) updated to 1 July 1988 APPENDIX II Pharmaco-therapeutic classification of medicines appearing in the alphabetical list in Appendix I updated to 1 July 1988 RESOLUTION AP (88) 2 ON THE CLASSIFICATION OF MEDICINES WHICH ARE OBTAINABLE ONLY ON MEDICAL PRESCRIPTION (superseding Resolution AP (82) 2) (Adopted by the Committee of Ministers on 22 September 1988 at the 419th meeting of the Ministers' Deputies) The Representatives on the Committee of Ministers of Belgium, France, the Federal Republic of Germany, Italy, Luxembourg, the Netherlands and the United Kingdom of Great Britain and Northern Ireland, these states being parties to the Partial Agreement in the social and public health field, and the Representatives of Austria, Denmark, Ireland, Spain and Switzerland, states which have participated in the public health activities carried out within the above-mentioned Partial Agreement since 1 October 1974, 2 April 1968, 23 September 1969, 21 April 1988 and 5 May 1964, respectively, Considering that the aim of the Council of Europe is to achieve greater unity between its members and that this
    [Show full text]
  • Ehealth DSI [Ehdsi V2.2.2-OR] Ehealth DSI – Master Value Set
    MTC eHealth DSI [eHDSI v2.2.2-OR] eHealth DSI – Master Value Set Catalogue Responsible : eHDSI Solution Provider PublishDate : Wed Nov 08 16:16:10 CET 2017 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 1 of 490 MTC Table of Contents epSOSActiveIngredient 4 epSOSAdministrativeGender 148 epSOSAdverseEventType 149 epSOSAllergenNoDrugs 150 epSOSBloodGroup 155 epSOSBloodPressure 156 epSOSCodeNoMedication 157 epSOSCodeProb 158 epSOSConfidentiality 159 epSOSCountry 160 epSOSDisplayLabel 167 epSOSDocumentCode 170 epSOSDoseForm 171 epSOSHealthcareProfessionalRoles 184 epSOSIllnessesandDisorders 186 epSOSLanguage 448 epSOSMedicalDevices 458 epSOSNullFavor 461 epSOSPackage 462 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 2 of 490 MTC epSOSPersonalRelationship 464 epSOSPregnancyInformation 466 epSOSProcedures 467 epSOSReactionAllergy 470 epSOSResolutionOutcome 472 epSOSRoleClass 473 epSOSRouteofAdministration 474 epSOSSections 477 epSOSSeverity 478 epSOSSocialHistory 479 epSOSStatusCode 480 epSOSSubstitutionCode 481 epSOSTelecomAddress 482 epSOSTimingEvent 483 epSOSUnits 484 epSOSUnknownInformation 487 epSOSVaccine 488 © eHealth DSI eHDSI Solution Provider v2.2.2-OR Wed Nov 08 16:16:10 CET 2017 Page 3 of 490 MTC epSOSActiveIngredient epSOSActiveIngredient Value Set ID 1.3.6.1.4.1.12559.11.10.1.3.1.42.24 TRANSLATIONS Code System ID Code System Version Concept Code Description (FSN) 2.16.840.1.113883.6.73 2017-01 A ALIMENTARY TRACT AND METABOLISM 2.16.840.1.113883.6.73 2017-01
    [Show full text]
  • Toxic, and Comatose-Fatal Blood-Plasma Concentrations (Mg/L) in Man
    Therapeutic (“normal”), toxic, and comatose-fatal blood-plasma concentrations (mg/L) in man Substance Blood-plasma concentration (mg/L) t½ (h) Ref. therapeutic (“normal”) toxic (from) comatose-fatal (from) Abacavir (ABC) 0.9-3.9308 appr. 1.5 [1,2] Acamprosate appr. 0.25-0.7231 1311 13-20232 [3], [4], [5] Acebutolol1 0.2-2 (0.5-1.26)1 15-20 3-11 [6], [7], [8] Acecainide see (N-Acetyl-) Procainamide Acecarbromal(um) 10-20 (sum) 25-30 Acemetacin see Indomet(h)acin Acenocoumarol 0.03-0.1197 0.1-0.15 3-11 [9], [3], [10], [11] Acetaldehyde 0-30 100-125 [10], [11] Acetaminophen see Paracetamol Acetazolamide (4-) 10-20267 25-30 2-6 (-13) [3], [12], [13], [14], [11] Acetohexamide 20-70 500 1.3 [15] Acetone (2-) 5-20 100-400; 20008 550 (6-)8-31 [11], [16], [17] Acetonitrile 0.77 32 [11] Acetyldigoxin 0.0005-0.00083 0.0025-0.003 0.005 40-70 [18], [19], [20], [21], [22], [23], [24], [25], [26], [27] 1 Substance Blood-plasma concentration (mg/L) t½ (h) Ref. therapeutic (“normal”) toxic (from) comatose-fatal (from) Acetylsalicylic acid (ASS, ASA) 20-2002 300-3502 (400-) 5002 3-202; 37 [28], [29], [30], [31], [32], [33], [34] Acitretin appr. 0.01-0.05112 2-46 [35], [36] Acrivastine -0.07 1-2 [8] Acyclovir 0.4-1.5203 2-583 [37], [3], [38], [39], [10] Adalimumab (TNF-antibody) appr. 5-9 146 [40] Adipiodone(-meglumine) 850-1200 0.5 [41] Äthanol see Ethanol -139 Agomelatine 0.007-0.3310 0.6311 1-2 [4] Ajmaline (0.1-) 0.53-2.21 (?) 5.58 1.3-1.6, 5-6 [3], [42] Albendazole 0.5-1.592 8-992 [43], [44], [45], [46] Albuterol see Salbutamol Alcuronium 0.3-3353 3.3±1.3 [47] Aldrin -0.0015 0.0035 50-1676 (as dieldrin) [11], [48] Alendronate (Alendronic acid) < 0.005322 -6 [49], [50], [51] Alfentanil 0.03-0.64 0.6-2.396 [52], [53], [54], [55] Alfuzosine 0.003-0.06 3-9 [8] 2 Substance Blood-plasma concentration (mg/L) t½ (h) Ref.
    [Show full text]
  • BMJ Open Is Committed to Open Peer Review. As Part of This Commitment We Make the Peer Review History of Every Article We Publish Publicly Available
    BMJ Open is committed to open peer review. As part of this commitment we make the peer review history of every article we publish publicly available. When an article is published we post the peer reviewers’ comments and the authors’ responses online. We also post the versions of the paper that were used during peer review. These are the versions that the peer review comments apply to. The versions of the paper that follow are the versions that were submitted during the peer review process. They are not the versions of record or the final published versions. They should not be cited or distributed as the published version of this manuscript. BMJ Open is an open access journal and the full, final, typeset and author-corrected version of record of the manuscript is available on our site with no access controls, subscription charges or pay-per-view fees (http://bmjopen.bmj.com). If you have any questions on BMJ Open’s open peer review process please email [email protected] BMJ Open Pediatric drug utilization in the Western Pacific region: Australia, Japan, South Korea, Hong Kong and Taiwan Journal: BMJ Open ManuscriptFor ID peerbmjopen-2019-032426 review only Article Type: Research Date Submitted by the 27-Jun-2019 Author: Complete List of Authors: Brauer, Ruth; University College London, Research Department of Practice and Policy, School of Pharmacy Wong, Ian; University College London, Research Department of Practice and Policy, School of Pharmacy; University of Hong Kong, Centre for Safe Medication Practice and Research, Department
    [Show full text]
  • (12) Patent Application Publication (10) Pub. No.: US 2011/0159073 A1 De Juan Et Al
    US 20110159073A1 (19) United States (12) Patent Application Publication (10) Pub. No.: US 2011/0159073 A1 de Juan et al. (43) Pub. Date: Jun. 30, 2011 (54) METHODS AND DEVICES FOR THE Publication Classification TREATMENT OF OCULAR CONDITIONS (51) Int. Cl. (76) Inventors: Eugene de Juan, LaCanada, CA A6F 2/00 (2006.01) (US); Signe E. Varner, Los (52) U.S. Cl. ........................................................ 424/427 Angeles, CA (US); Laurie R. Lawin, New Brighton, MN (US) (57) ABSTRACT Featured is a method for instilling one or more bioactive (21) Appl. No.: 12/981,038 agents into ocular tissue within an eye of a patient for the treatment of an ocular condition, the method comprising con (22) Filed: Dec. 29, 2010 currently using at least two of the following bioactive agent delivery methods (A)-(C): (A) implanting a Sustained release Related U.S. Application Data delivery device comprising one or more bioactive agents in a (63) Continuation of application No. 1 1/175,850, filed on posterior region of the eye so that it delivers the one or more Jul. 5, 2005, now abandoned. bioactive agents into the vitreous humor of the eye; (B) instill ing (e.g., injecting or implanting) one or more bioactive (60) Provisional application No. 60/585,236, filed on Jul. 2, agents Subretinally; and (C) instilling (e.g., injecting or deliv 2004, provisional application No. 60/669,701, filed on ering by ocular iontophoresis) one or more bioactive agents Apr. 8, 2005. into the vitreous humor of the eye. Patent Application Publication Jun. 30, 2011 Sheet 1 of 22 US 2011/O159073 A1 Patent Application Publication Jun.
    [Show full text]
  • Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DIX to the HTSUS—Continued
    20558 Federal Register / Vol. 60, No. 80 / Wednesday, April 26, 1995 / Notices DEPARMENT OF THE TREASURY Services, U.S. Customs Service, 1301 TABLE 1.ÐPHARMACEUTICAL APPEN- Constitution Avenue NW, Washington, DIX TO THE HTSUSÐContinued Customs Service D.C. 20229 at (202) 927±1060. CAS No. Pharmaceutical [T.D. 95±33] Dated: April 14, 1995. 52±78±8 ..................... NORETHANDROLONE. A. W. Tennant, 52±86±8 ..................... HALOPERIDOL. Pharmaceutical Tables 1 and 3 of the Director, Office of Laboratories and Scientific 52±88±0 ..................... ATROPINE METHONITRATE. HTSUS 52±90±4 ..................... CYSTEINE. Services. 53±03±2 ..................... PREDNISONE. 53±06±5 ..................... CORTISONE. AGENCY: Customs Service, Department TABLE 1.ÐPHARMACEUTICAL 53±10±1 ..................... HYDROXYDIONE SODIUM SUCCI- of the Treasury. NATE. APPENDIX TO THE HTSUS 53±16±7 ..................... ESTRONE. ACTION: Listing of the products found in 53±18±9 ..................... BIETASERPINE. Table 1 and Table 3 of the CAS No. Pharmaceutical 53±19±0 ..................... MITOTANE. 53±31±6 ..................... MEDIBAZINE. Pharmaceutical Appendix to the N/A ............................. ACTAGARDIN. 53±33±8 ..................... PARAMETHASONE. Harmonized Tariff Schedule of the N/A ............................. ARDACIN. 53±34±9 ..................... FLUPREDNISOLONE. N/A ............................. BICIROMAB. 53±39±4 ..................... OXANDROLONE. United States of America in Chemical N/A ............................. CELUCLORAL. 53±43±0
    [Show full text]
  • Psychotic Disorder Due to Withdrawal of Barbexaclone Barbeksaklon Yoksunluğuna Bağlı Psikotik Bozukluk
    Letter to the Editor 87 DOI: 10.4274/Npa.y 6310 Psychotic Disorder due to Withdrawal of Barbexaclone Barbeksaklon Yoksunluğuna Bağlı Psikotik Bozukluk Murat KULOĞLU1, Sevda KORKMAZ2, Sadullah SAĞLAM3, Murad ATMACA1 1Fırat University Hospital Psychiatry Clinic, Elazığ, Turkey 2Elazığ Psychiatry Hospital, Psychiatry Clinic, Elazığ, Turkey 3Elazığ Psychiatry Hospital, Neurology Clinic, Elazığ, Turkey Dear Editor, which became generalized. He had approximately 3-4 seizures a year. It was learned that the patient who had these complaints Barbexaclone (Maliasin®) is an antiepileptic drug which is for the last three days discontinued barbexaclone two days composed of phenobarbital and salt compound of before the onset of the symptoms. Epileptic seizure was not propylhexedrine which is known to be a central nervous system described in the initial period of the complaints. The patient who stimulant . It has been reported that psychotic symptoms may had no previous history of psychiatric disease had no physical rarely develop during treatment with phenobarbital and other illness except for epilepsy. Complete blood count, biochemical antiepileptic drugs (1). Although there are case reports in the tests and thyroid function tests were within normal limits. On literature about development of addiction with barbexaclone (2), neurological examination, his consciousness was open, he had there is no information about development of psychotic disorder full orientation to place, time and person. However, full with discontinuance after long-term use. In our article, we aimed cooperation could not be established with the patient because of to present a patient who developed psychotic symptoms and active psychotic symptoms. The patient had disarthric speech. some behavioral changes with sudden discontinuance of On psychiatric examination, it was observed that he had barbexaclone.
    [Show full text]
  • Stembook 2018.Pdf
    The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances FORMER DOCUMENT NUMBER: WHO/PHARM S/NOM 15 WHO/EMP/RHT/TSN/2018.1 © World Health Organization 2018 Some rights reserved. This work is available under the Creative Commons Attribution-NonCommercial-ShareAlike 3.0 IGO licence (CC BY-NC-SA 3.0 IGO; https://creativecommons.org/licenses/by-nc-sa/3.0/igo). Under the terms of this licence, you may copy, redistribute and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that WHO endorses any specific organization, products or services. The use of the WHO logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons licence. If you create a translation of this work, you should add the following disclaimer along with the suggested citation: “This translation was not created by the World Health Organization (WHO). WHO is not responsible for the content or accuracy of this translation. The original English edition shall be the binding and authentic edition”. Any mediation relating to disputes arising under the licence shall be conducted in accordance with the mediation rules of the World Intellectual Property Organization. Suggested citation. The use of stems in the selection of International Nonproprietary Names (INN) for pharmaceutical substances. Geneva: World Health Organization; 2018 (WHO/EMP/RHT/TSN/2018.1). Licence: CC BY-NC-SA 3.0 IGO. Cataloguing-in-Publication (CIP) data.
    [Show full text]
  • CEL MAI KO NA NA NA NA NA (12 ) United States Patent ( 10 ) Patent No
    US010064856B2CEL MAI KO NA NA NA NA NA (12 ) United States Patent ( 10 ) Patent No. : US 10 , 064 ,856 B2 Bosse et al. ( 45 ) Date of Patent: * Sep . 4 , 2018 ( 54 ) PHARMACEUTICAL COMPOSITIONS (52 ) U .S . CI. ??? . .. A61K 31/ 485 ( 2013 .01 ) ; A61K 9 / 209 @(71 ) Applicant : LOCL PHARMA , INC . , Las Vegas , ( 2013 . 01 ) ; A61K 9 / 2013 ( 2013 . 01 ) ; A61K NV ( US ) 9 /2027 ( 2013 .01 ) ; A61K 9 / 2054 ( 2013 .01 ) ; A61K 9 / 4808 ( 2013 .01 ) ; A61K 31 / 165 @(72 ) Inventors : Paul Bosse, Jupiter , FL (US ) ; John ( 2013 .01 ) ; A61K 31/ 167 ( 2013 .01 ) ; A61K Ameling , Jupiter, FL (US ) ; Bernard 31/ 24 ( 2013 .01 ) ; A6IK 31/ 403 ( 2013 .01 ) ; Schachtel, Jupiter, FL (US ) ; Ray A61K 31/ 404 (2013 .01 ) ; A61K 31 /4196 Takigiku , Loveland , OH (US ) ( 2013 . 01 ) ; A61K 31/ 422 ( 2013 . 01 ) ; A61K 31 / 437 ( 2013 .01 ) ; A61K 31/ 454 ( 2013 .01 ) ; @( 73 ) Assignee : LOCAL PHARMA , INC ., Las Vegas , A61K 31 /515 ( 2013 . 01 ) ; A61K 31/ 522 ( 2013 . 01 ) ; A61K 31 /5415 ( 2013 .01 ) ; A61K NV (US ) 45 / 06 ( 2013 .01 ) ; A61K 9 / 0024 ( 2013 .01 ) ; @( * ) Notice : Subject to any disclaimer , the term of this A61K 9 / 0056 ( 2013 . 01 ) ; A61K 9 / 1694 patent is extended or adjusted under 35 ( 2013 . 01 ) ; A61K 9 /2086 ( 2013 . 01 ) ; A61K U . S . C . 154 (b ) by 0 days . 47 / 36 ( 2013 .01 ) (58 ) Field of Classification Search This patent is subject to a terminal dis None claimer . See application file for complete search history . ( 21 ) Appl. No .: 15 / 683, 635 ( 56 ) References Cited ( 22 ) Filed : Aug . 22, 2017 U . S . PATENT DOCUMENTS 3 ,048 , 526 A 8 / 1962 Boswell (65 ) Prior Publication Data 3 , 108 , 046 A 10 / 1963 Harbit 3 , 536 ,809 A 10 / 1970 Norman US 2017 /0348303 A1 Dec .
    [Show full text]
  • Pharmaceutical Composition with Synergistic Anticonvulsant Effect
    (19) TZZ __T (11) EP 2 695 618 A1 (12) EUROPEAN PATENT APPLICATION (43) Date of publication: (51) Int Cl.: 12.02.2014 Bulletin 2014/07 A61K 38/04 (2006.01) A61P 21/00 (2006.01) A61P 19/00 (2006.01) A61P 25/14 (2006.01) (2006.01) (21) Application number: 13004798.8 A61K 31/40 (22) Date of filing: 15.06.2007 (84) Designated Contracting States: (71) Applicant: UCB Pharma GmbH AT BE BG CH CY CZ DE DK EE ES FI FR GB GR 40789 Monheim (DE) HU IE IS IT LI LT LU LV MC MT NL PL PT RO SE SI SK TR (72) Inventor: Stöhr, Thomas 2400 Mol (BE) (30) Priority: 15.06.2006 US 813967 P 12.10.2006 EP 06021470 (74) Representative: Dressen, Frank 12.10.2006 EP 06021469 UCB Pharma GmbH 22.11.2006 EP 06024241 Alfred-Nobel-Strasse 10 40789 Monheim (DE) (62) Document number(s) of the earlier application(s) in accordance with Art. 76 EPC: Remarks: 07764676.8 / 2 037 965 This application was filed on 04-10-2013 as a divisional application to the application mentioned under INID code 62. (54) PHARMACEUTICAL COMPOSITION WITH SYNERGISTIC ANTICONVULSANT EFFECT (57) The present invention is directed to a pharmaceutical composition comprising (a) lacosamide and (b) levetira- cetam for the prevention, alleviation or/and treatment of epileptic seizures. EP 2 695 618 A1 Printed by Jouve, 75001 PARIS (FR) EP 2 695 618 A1 Description [0001] The present application items the priorities of US 60/813.967 of 15 June 2006, EP 06 021 470.7 of 12 October 2006, EP 06 021 469.9 of 12 October 2006, and EP 06 024 241.9 of 22 November 2006, which are included herein by 5 reference.
    [Show full text]